iMediSync

Home
South Korea
Seoul
iMediSync

Call Directions Website Contact the business

iMediSync is an AI-driven early detection therapeutic platform for optimal brain health.

AI Brain Mapping with EEG
Neuromodulation with NIR-LED
For memory, attention impulsiveness, mood, trauma Core Technology Features

- AI-based Automatic Denoising Technology
- Innovative EEG Feature Engineering Technology Using Machine Learning Techniques
- Innate High Quality of Normative EEG DB Covering from Young Kids to Elderlies
- Capability of Expanding the Neurological Field – Research Network locally and globally

-------------------------------------------

Our Products

- iSyncBrain® (https://isyncbrain.com) is an AI driven analysis cloud platform. It has been registered as a class II medical device by the Korean FDA, and users from more than 30 countries are using the platform.

- "iSyncBrain® – MCI Classifier," our early detection EEG algorithm for aMCI, was developed and clinically validated with three Korean university hospitals (sensitivity, specificity >90%). It also got the clearance from Korean FDA as a class II medical device for (different underlying pathology)

- "iSyncWave™" provides AI-driven cloud based EEG (electroencephalogram) brain mapping and personalized LED therapeutics. Especially, iSyncWave™ uses dry sensors and doesn’t need gel paste as conventional EEG devices do. It also provides personalized LED therapeutics called photobiomodulation (PBM) according to the brain mapping results; as it can also be paired with iSyncMe® – mobile app, it will add a feature to connect patients and doctors virtually in the near future.

- iSyncHeart®is an AI cloud-based solution for heart rate variability (HRV). It was launched and has been registered as a class II medical device by the Korean FDA. It has been used for remote ECG monitoring of participants in clinical trials.

21/09/2026

iMediSync at the 33rd ALD Annual Conference

We’re excited to share that Kody Newman, BS will be speaking at the 33rd ALD Annual Conference & Exhibition in Las Vegas, October 15–17, 2026.

His session will focus on EEG-guided photobiomodulation, including personalized dosing approaches, brain targeting, and emerging cognitive and neuropsychiatric applications.

It’s a great opportunity to see how qEEG can help make PBM more individualized and clinically informed.

📍 Sahara Hotel, Las Vegas
📅 October 15–17, 2026

Register at:
laserdentistry.org

Use code NEWMAN10 for 10% off registration.

18/09/2026

One participant shares what made our workshop easy to understand and informative, plus how they’re using iMediSync—including PBM—in clinical practice.

16/09/2026

One workshop participant shares how brain mapping can help clinicians better understand patients and guide their care.

14/09/2026

Hear one participant’s experience at our workshop. Stay tuned for our next workshop announcement, coming soon!

04/09/2026

A treatment only works when people can actually use it consistently.
That is one of the most practical findings from a new Neurotherapeutics study using the iSyncMe.
Participants self-administered 15-minute tPBM sessions at home, five days per week, for five weeks. Adherence across the neuromodulation program reached 98%, with device logs and weekly remote check-ins used to monitor participation.
The tPBM protocol delivered near-infrared light through 19 scalp locations and included three phases:
Posterior stimulation at 10 Hz
Whole-head stimulation at 15 Hz
Frontal stimulation at 18 Hz
Researchers designed the protocol to support brain regions involved in visual processing, widespread cortical regulation, and prefrontal control over reward-driven behavior.
Participants receiving tPBM showed significant reductions in alcohol craving and alcohol-use severity. The combined tPBM and vagus nerve stimulation group also had the highest odds of improving overall drinking behavior.
The study was open-label and did not include a sham group, so the results should be considered promising rather than definitive. But it demonstrates that structured, remotely supervised PBM can be practical outside the clinic.
That matters for any treatment that depends on repetition and consistency.
Learn more: imedisyncamericas.com
Reference:
Kwon M, Park M, Kim M, et al. The effectiveness of transcranial photobiomodulation therapy and transauricular vagus nerve stimulation on reducing alcohol craving. Neurotherapeutics. 2026;23:e00937.
https://doi.org/10.1016/j.neurot.2026.e00937

03/09/2026

A newly published study in Neurotherapeutics tested whether home-based transcranial photobiomodulation could help reduce alcohol craving.
Sixty participants were randomized to receive:
tPBM with the iSyncMe
transauricular vagus nerve stimulation
or both treatments together
Participants used the devices at home for 15 minutes per session, five times per week, for five weeks.
The results were encouraging. The tPBM group showed a significant reduction in alcohol craving, with average PACS scores dropping from 7.32 to 4.11. Nearly 79% of participants receiving tPBM achieved at least a 30% reduction in craving, compared with 30% in the vagus nerve stimulation group.
The study also reported significant improvements in alcohol-use severity and depressive symptoms in the tPBM group.
This was an open-label study in people with subclinical alcohol use, not diagnosed alcohol use disorder, so larger sham-controlled trials are still needed.
Still, the findings add to the growing evidence that home-based PBM may support the brain networks involved in craving and self-control.
Learn more: imedisyncamericas.com
Reference:
Kwon M, Park M, Kim M, et al. The effectiveness of transcranial photobiomodulation therapy and transauricular vagus nerve stimulation on reducing alcohol craving. Neurotherapeutics. 2026;23:e00937.
https://doi.org/10.1016/j.neurot.2026.e00937

02/09/2026

Daily Dry EEG Can Track Brain Changes During Intensive Depression Treatment
A new pilot study used the iSyncWave to record qEEG every day during an accelerated iTBS program for treatment-resistant depression.
Ten participants received eight iTBS sessions per day for five days. Dry EEG was recorded at baseline and after each treatment day.
The practical result was clear:
Every participant completed all six EEG recordings
Setup took about 8–12 minutes
No headset-related adverse events were reported
Every recording produced usable data
Signal quality remained stable across the week
The clinical and EEG findings were also encouraging. Average MADRS depression scores fell from 27.7 at baseline to 11.8 after five days, while frontal Alpha 1 activity progressively decreased in regions near the prefrontal stimulation target. Changes in frontal alpha asymmetry were also associated with changes in depression and anxiety scores.
This was a small, interim pilot study, so larger trials are still needed. But it demonstrates something immediately useful: dry EEG can be integrated into an intensive neuromodulation workflow without adding the time and cleanup of conventional wet EEG.
Instead of measuring the brain only before and after treatment, clinicians may eventually be able to watch it change day by day.
Learn more: imedisyncamericas.com
Reference:
Vasileiadi, M., Nona, C. N., Silver, D., et al. Daily Dry-Electrode EEG Tracks Alpha Changes During Accelerated iTBS in Treatment-Resistant Depression.

01/09/2026

Coming soon in Biological Psychiatry: new research using iSyncWave during accelerated iTBS for treatment-resistant depression.
The study explores whether serial dry qEEG monitoring can be used throughout an accelerated intermittent theta burst stimulation program.
This matters because conventional qEEG can be time-consuming and difficult to repeat frequently. Dry EEG makes rapid, daily sampling much more practical.
The researchers used the iMediSync iSyncWave to evaluate feasibility and explore whether changes in EEG frequency bands may help predict treatment response.
The full findings are not available yet, but this is an important step toward combining neuromodulation with objective, repeatable brain monitoring.
We’ll share more when the full abstract and results become available.
Reference:
Vasileiadi, M., Nona, C., Silver, D., et al. (2026). Feasibility of Serial Dry-EEG Monitoring During Accelerated iTBS for Treatment Resistant Depression. Biological Psychiatry, 99(10), S152–S153.
imedisyncamericas.com

31/08/2026

Psychiatry has always depended heavily on what patients report and what clinicians observe.
That information matters, but symptoms often overlap. Poor concentration can appear in ADHD, depression, anxiety, trauma, sleep problems, and cognitive decline. Two patients can describe nearly identical symptoms while having very different patterns of brain activity.
A new review in the Journal of Personalized Medicine examines how qEEG can add objective neurophysiological data to the assessment process.
qEEG can measure:
• Activity across delta, theta, alpha, beta, and gamma frequencies
• Differences between the left and right hemispheres
• Connectivity between brain regions
• The likely cortical sources of abnormal activity
• Changes in brain function during treatment
This does not replace the clinical interview or establish a diagnosis on its own. It gives clinicians another layer of information when symptoms alone do not tell the full story.
With modern dry, wireless EEG systems, collecting that information is becoming much more practical for everyday clinics.
Precision psychiatry starts with understanding the individual brain—not simply assigning everyone with similar symptoms to the same category.
Learn more: imedisyncamericas.com
Schedule a demo: imedisyncamericas.com/demoschedule
Reference:
Amico, F., Shannon, S., & Rondeau, S. (2026). Quantitative Electroencephalography as a Complement to Symptom-Based Psychiatric Diagnosis: A Narrative Review. Journal of Personalized Medicine, 16, 261.
https://doi.org/10.3390/jpm16050261

28/08/2026

Why Dry EEG Is Better for Everyday Clinics
Traditional EEG can take time. Gel has to be applied, electrodes need preparation, and the patient usually leaves with a cleanup job afterward.
Dry EEG removes much of that friction.
With the iSyncWave, clinicians can: ⚡ Set up and begin recording quickly
🧼 Collect EEG data without gel or paste
📱 Move the system easily between rooms or locations
📊 Send recordings for rapid cloud-based qEEG report generation
🔁 Repeat scans more easily to monitor changes over time
The biggest advantage is convenience. When an EEG is faster and easier to perform, clinics can use brain data more regularly—not only for unusual or complex cases.
No gel. Less setup. Faster access to useful information. (remove from caption, used in post. -AS 8.11)
Learn more: imedisyncamericas.com
Schedule a demo: imedisyncamericas.com/demoschedule

Address

5F, TIPS TOWN 3, 175 Yeoksam-ro
Seoul
06247

Telephone

+8227477422

Website

http://www.imedisync.com/

Alerts

Be the first to know and let us send you an email when iMediSync posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Business

Send a message to iMediSync: